Waldencast plc (WALD) filed Form 15 on October 15, 2026, to terminate registration under Section 12(g) of its Class A ordinary shares and redeemable warrants and suspend reporting obligations under Section 15(d) of the Exchange Act. Upon filing, its obligation to file periodic and current SEC reports, including Form 20-F annual reports and Form 6-K current reports, was suspended immediately. Deregistration is expected to become effective 90 days after filing or sooner if the SEC determines a shorter period.
Each whole warrant is exercisable for one Class A ordinary share at $11.50 per share. As of October 5, 2026, Waldencast's Class A ordinary shares and warrants were quoted on the Pink Limited market of OTC Markets Group under MLKMF and MLKWF, respectively.
Waldencast plc (WALD) filed a Form 15 to terminate registration under Section 12(g) for its Class A ordinary shares and redeemable warrants. Each warrant is exercisable for one Class A ordinary share at an exercise price of $11.50 per share.
Waldencast plc completed the sale of its Obagi Medical business to Bridgepoint on July 30, 2026, in a transaction valued at up to $460 million. At closing, it repaid $178.4 million of outstanding indebtedness under the Lumina Credit Agreement in full and received $149.9 million in net cash proceeds after placing $3.0 million in escrow. Obagi results are presented as discontinued operations.
For the six months ended June 30, 2026, continuing-operations revenue was $26.1 million, down 57.1% from $60.9 million; net loss was $94.9 million, up 96.5% from $48.3 million; and Adjusted EBITDA was negative $23.2 million versus $0.02 million. Continuing-operations cash and cash equivalents were $138.6 million as of August 31, 2026. The Board approved voluntary delisting and deregistration of its Class A ordinary shares and warrants from Nasdaq; after delisting, the company intends to seek OTC quotation under MLKM. Waldencast describes a goal to double 2025 revenue over five years and build toward an Adjusted EBITDA margin in the mid-20s once Milk Makeup is back at scale, calling this a North Star rather than financial guidance.
Waldencast plc filed Form 25 on September 24, 2026, to remove its Class A ordinary shares and redeemable warrants from Nasdaq listing and deregister them under Section 12(b) of the Exchange Act. Each whole warrant is exercisable for one Class A ordinary share at $11.50 per share.
The last Nasdaq trading day is expected to be on or about October 2, 2026, and delisting is expected to become effective on or about October 4, 2026. Section 12(b) deregistration is expected to become effective 90 days after the Form 25 filing. Waldencast intends to file Form 15 on or about October 5, 2026; upon filing, its reporting obligations under Sections 12(g) and 15(d) will be suspended immediately. The company reserves the right to withdraw or postpone the filings before they become effective.
Waldencast plc submitted a Form 25 notification concerning removal from Nasdaq listing and Section 12(b) registration of its Class A ordinary shares and redeemable warrants. Each warrant is exercisable for one Class A ordinary share at $11.50 per share; the ordinary shares have a par value of $0.0001 per share. The company certified that it had reasonable grounds to believe it met the Form 25 filing requirements.
Waldencast plc (WALD) plans to voluntarily delist its Class A ordinary shares and warrants from Nasdaq and deregister these securities under the U.S. Exchange Act. It intends to file Form 25 on or about September 24, 2026, with Nasdaq trading expected to end on or about October 2, 2026.
On or about October 5, 2026, Waldencast expects to file Form 15, which would immediately suspend its SEC reporting duties, with deregistration under Section 12(b) effective about 90 days after Form 25. The Board cited high U.S. listing and compliance costs, limited trading liquidity, and reduced dependence on U.S. equity markets after divesting Obagi Medical. Central headquarters costs were $18.5 million in 2025, and the Board expects a substantial portion to be eliminated after delisting and deregistration. Subject to shareholder approval, the company will seek to rename itself Milk Makeup plc and pursue quotation of its Class A shares on an over-the-counter market under the ticker “MLKM”, though there is no guarantee an OTC market will develop.
Waldencast plc (WALD) reported an insider-related purchase of Class A ordinary shares linked to director and ten-percent owner Cristiano Souza. On August 28, 2026, Zeno Investment Master Fund, for which Souza is an indirect controller, purchased 335,000 Class A shares at $1.5094 per share from Waldencast Ventures LP, bringing its indirectly held position reported for Souza to 12,587,580 shares. Souza disclaims beneficial ownership of the fund’s holdings except to the extent of his pecuniary interest.
Waldencast plc reported that CEO Michel Brousset returned 264,294 restricted stock units to the company in a disposition to the issuer at $2.00 per unit, leaving 0 units from this award. The repurchase was tied to the sale of its Obagi Medical dermatological skincare and aesthetics business, after which he transitioned to lead Obagi Medical.
Waldencast plc reported that Chief Growth Officer and director Hind Sebti disposed of 193,816 Restricted Stock Units, each representing one Class A ordinary share, in a disposition to the issuer at $2.00 per RSU. The RSUs were purchased by Waldencast in connection with the completion of the sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026, when Sebti transitioned to lead Obagi Medical. These RSUs came from an October 30, 2024 grant of 290,723 RSUs that had been scheduled to vest in three annual tranches, and following this transaction no RSUs from this grant remain reported for Sebti.
Waldencast plc’s Chief Financial Officer, Manuel Manfredi, reported the accelerated vesting and settlement of 79,289 restricted stock units (RSUs) into the same number of Class A ordinary shares on July 30, 2026. This occurred upon completion of Waldencast’s sale of its Obagi Medical dermatological skincare and aesthetics business, after which he transitioned to lead Obagi Medical. Following the settlement, he directly holds 118,933 Class A ordinary shares. A prior grant of 118,933 RSUs dated October 30, 2024 had originally been scheduled to vest in three annual tranches.